John D. Reveille, Lihi Eder, Nelly Ziade, Percival D. Sampaio-Barros, Tae-Hwan Kim, Nurullah Akkoç, Matthew A. Brown
{"title":"Global epidemiology of spondyloarthritis","authors":"John D. Reveille, Lihi Eder, Nelly Ziade, Percival D. Sampaio-Barros, Tae-Hwan Kim, Nurullah Akkoç, Matthew A. Brown","doi":"10.1038/s41584-025-01286-x","DOIUrl":"10.1038/s41584-025-01286-x","url":null,"abstract":"The worldwide epidemiology of axial spondyloarthritis (axSpA), psoriatic arthritis (PsA) and peripheral spondyloarthritis, as well as of HLA-B27 and other MHC and non-MHC genes in these diseases, is reviewed herein. The frequency of axSpA is highest in circumpolar groups (such as Sami people and certain Indigenous American groups) and lowest in those of Japanese and African ancestry. The same pattern holds for PsA, although the overall prevalence of PsA seems much lower in East Asia, where it is less frequent than axSpA. The prevalence of PsA in people with psoriasis is increased where rheumatological assessment was carried out and seems to be increasing over time. HLA-B27 remains the most important genetic factor in axSpA susceptibility, although its frequency is lower in African American, South American and Middle Eastern populations than in others. The presence of HLA-B27 and other HLA alleles seems to be important in discerning clinical subsets of SpA and PsA, particularly those characterized by acute anterior uveitis or by axSpA with psoriasis, although these HLA-B27 and other MHC and non-MHC associations are derived from genome-wide association studies and other chip-based studies in large populations. These studies have been carried out mainly in populations of European and East Asian ancestry, and similar data from Latin America, sub-Saharan Africa and South Asia are lacking. This under-representation is an unmet need in applying genetic factors to understand the pathogenesis, diagnosis and classification of SpA and PsA. This article provides a comprehensive overview of the epidemiology of spondyloarthritis — including axial spondyloarthritis, psoriatic arthritis and peripheral spondyloarthritis — worldwide, as well as the epidemiology of genetic factors implicated in these diseases.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"21 10","pages":"580-598"},"PeriodicalIF":32.7,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145059336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clément Triaille, Marie-Louise Frémond, Augusto Vaglio
{"title":"Inborn errors of immunity and AAV: a complex picture","authors":"Clément Triaille, Marie-Louise Frémond, Augusto Vaglio","doi":"10.1038/s41584-025-01299-6","DOIUrl":"https://doi.org/10.1038/s41584-025-01299-6","url":null,"abstract":"<p>We read with great interest the manuscript by Gül et al. on monogenic systemic vasculitis (Gül, A. et al. The pathogenesis, clinical presentations and treatment of monogenic systemic vasculitis. <i>Nat. Rev. Rheumatol.</i> <b>21</b>, 414–425 (2025))<sup>1</sup>. We thank the authors for presenting a detailed synthesis of current knowledge on the clinical features of these genetic disorders and the putative mechanisms that link different genetic defects to vascular inflammation. Gül et al.<sup>1</sup> also discuss the potential relevance of these genes (and their associated pathways) for the sporadic forms of vasculitis that they clinically resemble. We would like to provide further comments on the genetic defects associated with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV).</p><p>First, although a robust link between AAV and specific genetic disorders (particularly among type I interferonopathies) is emerging, much progress is still needed to better understand the nature of this association<sup>2</sup>. For instance, ANCA specificity and titres are lacking in many studies that describe these conditions, as is their association with specific small vessel vasculitis manifestations (such as alveolar vasculitis and pauci-immune glomerulonephritis). These aspects are indeed crucial to assess the pathogenic value of ANCA (that is, the presence of true AAV), as opposed to an unspecific biological sign of autoimmunity.</p>","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"16 1","pages":""},"PeriodicalIF":33.7,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145017625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ahmet Gül, Ivona Aksentijevich, Paul Brogan, Marco Gattorno, Peter C. Grayson, Seza Ozen
{"title":"Reply to ‘Inborn errors of immunity and AAV: a complex picture’","authors":"Ahmet Gül, Ivona Aksentijevich, Paul Brogan, Marco Gattorno, Peter C. Grayson, Seza Ozen","doi":"10.1038/s41584-025-01298-7","DOIUrl":"https://doi.org/10.1038/s41584-025-01298-7","url":null,"abstract":"<p>We thank Clément Triaille, Marie-Louise Frémond and Augusto Vaglio for their interest in our Review (Gül, A et al. The pathogenesis, clinical presentations and treatment of monogenic systemic vasculitis. <i>Nat. Rev. Rheumatol.</i> <b>21</b>, 414–425 (2025))<sup>1</sup>, and for providing additional examples of monogenic disorders that can be associated with the development of anti-neutrophil cytoplasm antibodies (ANCA) and vasculitic manifestations (Triaille, C., Frémond, M. L. & Vaglio, A. Inborn errors of immunity and AAV: a complex picture. <i>Nat. Rev. Rheumatol.</i> https://doi.org/10.1038/s41584-025-01299-6 (2025))<sup>2</sup>.</p><p>In our Review<sup>1</sup>, we focused on monogenic autoinflammatory diseases that present with findings of vasculitis involving blood vessels of all sizes and types. The pathogenic mechanisms underlying these conditions are complex and include the activation of myeloid cells, type I interferon-driven autoimmune responses, dysregulated adaptive immunity, endothelial dysfunction and injury and thrombotic vasculopathies.</p>","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"28 1","pages":""},"PeriodicalIF":33.7,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145017624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The epidemiology of RA","authors":"Axel Finckh","doi":"10.1038/s41584-025-01297-8","DOIUrl":"https://doi.org/10.1038/s41584-025-01297-8","url":null,"abstract":"Analysis of regional variations in the epidemiology of rheumatoid arthritis (RA) over the past 40 years indicates that the age-standardized incidence of RA has increased — and is expected to continue rising — while the mortality and morbidity of the disease are decreasing. As a result, the number of years lived with disability and the overall disease burden attributable to RA have increased and are projected to rise further.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"35 1","pages":""},"PeriodicalIF":33.7,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145017914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jörg H. W. Distler, Masataka Kuwana, Shervin Assassi, Christopher P. Denton
{"title":"Emerging therapies for the treatment of systemic sclerosis","authors":"Jörg H. W. Distler, Masataka Kuwana, Shervin Assassi, Christopher P. Denton","doi":"10.1038/s41584-025-01294-x","DOIUrl":"10.1038/s41584-025-01294-x","url":null,"abstract":"Systemic sclerosis (SSc) is an autoimmune disease in which fibrotic, vascular, autoimmune and fibrotic mechanisms synergize to promote disease progression. SSc is associated with high morbidity and mortality, primarily owing to fibrotic tissue remodelling and subsequent organ failure. Despite progress with the approval of novel therapies, mortality remains high; approximately half of the people diagnosed with SSc will succumb to disease. This statistic highlights the considerable need for novel, effective therapies. Indeed, SSc has become a disease with very active drug development. Numerous drugs with different modes of actions are currently evaluated in or are about to enter clinical trials in SSc. These clinical trials provide hope for effectively slowing or even halting the progression of fibrosis and thereby further improving outcomes for patients with SSc. This Review provides a comprehensive overview of emerging therapies for the treatment of systemic sclerosis. The authors highlight novel therapeutic targets and emphasize the need for precision medicine approaches for the effective treatment of this disease.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"21 10","pages":"612-625"},"PeriodicalIF":32.7,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145009244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Integrin α11 on fibroblast-like synoviocytes promotes joint damage in arthritis","authors":"Holly Webster","doi":"10.1038/s41584-025-01301-1","DOIUrl":"10.1038/s41584-025-01301-1","url":null,"abstract":"Findings indicate that the collagen-binding integrin α11 could be a therapeutic target for rheumatoid arthritis.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"21 10","pages":"577-577"},"PeriodicalIF":32.7,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144995350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Two subsets of TPH cells with distinct functions in RA","authors":"Maria Papatriantafyllou","doi":"10.1038/s41584-025-01300-2","DOIUrl":"10.1038/s41584-025-01300-2","url":null,"abstract":"Stem-like and effector-like peripheral helper T cells have distinct functions in rheumatoid arthritis.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"21 10","pages":"577-577"},"PeriodicalIF":32.7,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144995349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Immune-cell profiling to guide stratification and treatment of patients with rheumatic diseases","authors":"Deepak A. Rao","doi":"10.1038/s41584-025-01291-0","DOIUrl":"https://doi.org/10.1038/s41584-025-01291-0","url":null,"abstract":"<p>Methods for high-dimensional immune-cell profiling have advanced dramatically in the past decade. Studies of tissue and blood samples from patients with rheumatic diseases have revealed stereotyped features of immune dysregulation in individual diseases and in subsets of patients who share diagnosis of a heterogeneous disease. Translating immunological patterns into clinically implementable, actionable biomarkers has the potential to improve detection and quantification of pathological immune activity and selection of appropriate treatments for autoimmune rheumatic diseases. For example, cytometric features can be used to distinguish the various forms of inflammatory arthritis, stratify subsets of patients with rheumatoid arthritis or subsets of patients with systemic lupus erythematosus and predict treatment responses. Cellular immune profiling also enables the identification of specific features of immune dysregulation in individuals with rare, undiagnosed, inflammatory diseases. Several paths might lead to translation of discoveries from broad immune profiling into clinical tests to interrogate immune activation in people with rheumatic diseases.</p>","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"24 1","pages":""},"PeriodicalIF":33.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
David S. Pisetsky, Amanda M. Eudy, Jennifer L. Rogers, Ru-Rong Ji, Katherine T. Martucci, Camilla Svensson, Peter E. Lipsky
{"title":"Pain in systemic lupus erythematosus: emerging insights and paradigms","authors":"David S. Pisetsky, Amanda M. Eudy, Jennifer L. Rogers, Ru-Rong Ji, Katherine T. Martucci, Camilla Svensson, Peter E. Lipsky","doi":"10.1038/s41584-025-01290-1","DOIUrl":"10.1038/s41584-025-01290-1","url":null,"abstract":"Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by protean clinical manifestations that are associated with immune system dysregulation. Of these manifestations, pain and pain-related symptoms such as fatigue, mood disturbance and cognitive impairment are the most common features reported by patients and represent important determinants of quality of life. Nevertheless, the relationship of these symptoms to underlying immune mechanisms is unclear. To advance scientific study and patient-centric care, this Review will consider the origin of pain in SLE and the clinical ramifications. Although many of the inflammatory aspects of SLE, including arthritis, serositis and skin disease, can be associated with nociceptive pain, patients frequently report pain that seems out of proportion to the degree of inflammation. In many of these patients, pain might reflect central and peripheral nervous system sensitization that mediates nociplasticity, a change in brain processing; with nociplasticity, changes in neuronal function and brain connections can amplify the experience of pain and pain-related symptoms. The close interplay between the immune and the nervous systems means that widespread pain and the associated symptoms can be considered as essential features of SLE; these features might share pathogenic mechanisms with other autoimmune diseases and nociplastic pain syndromes such as fibromyalgia. In systemic lupus erythematosus (SLE), pain is one of the most commonly reported and debilitating symptoms. The authors of this Review highlight the importance of understanding the mechanisms of pain in SLE and addressing pain and pain-associated symptoms in the management of SLE.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"21 10","pages":"626-639"},"PeriodicalIF":32.7,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144905872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Looking to the new horizon in rheumatology research","authors":"Elizabeth C. Rosser, Lucy R. Wedderburn","doi":"10.1038/s41584-025-01295-w","DOIUrl":"https://doi.org/10.1038/s41584-025-01295-w","url":null,"abstract":"The future of rheumatology research will be defined by the growing era of personalized and stratified medicine, with a focus on establishing drug-free remission. In the face of substantial global upheaval, now is the time to ensure no patient group is left behind by prioritizing research equity and inclusion.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"742 1","pages":""},"PeriodicalIF":33.7,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144840026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}